Akero Therapeutics

At Akero Therapeutics, we are at the forefront of biopharmaceutical innovation, pioneering groundbreaking technology to combat serious metabolic diseases with high unmet medical needs. Our primary focus is on revolutionizing the treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH), a severe condition for which there are currently no approved therapies. Through rigorous scientific exploration and a commitment to clinical excellence, we are developing transformative treatments designed to restore metabolic balance and dramatically improve the lives of patients globally. Our work is centered on harnessing novel biology to create therapeutics that address the root causes of complex metabolic disorders, moving beyond mere symptom management to offer potentially curative solutions.

Our lead product candidate, efruxifermin (EFX), exemplifies our innovative approach. EFX is an engineered analog of fibroblast growth factor 21 (FGF21), a crucial hormone that regulates the metabolism of lipids, carbohydrates, and proteins. By mimicking and enhancing the body's natural metabolic processes, EFX has demonstrated the potential to reduce liver fat, mitigate inflammation, and reverse fibrosis—the key pathological drivers of MASH. Our comprehensive clinical development program, including the HARMONY, SYMMETRY, and the broader Phase 3 SYNCHRONY studies, is meticulously designed to evaluate the efficacy and safety of EFX across different stages of MASH, from pre-cirrhotic states to compensated cirrhosis. We are driven by a vision to deliver a foundational monotherapy that not only halts disease progression but also reverses existing liver damage, offering new hope to millions of patients and reshaping the future of metabolic disease treatment.